Physician profile
Hayden Long
NPI 1700093598
$386,169.47
in general payments reported to CMS, 2019-2025
56 companies · $99K in 2025
The $99K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,629 · 2020: $11K · 2021: $80K · 2022: $68K · 2023: $39K · 2024: $87K · 2025: $99K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $195K · Food and Beverage: $16K · Travel and Lodging: $9,447 · Consulting Fee: $3,420 · Education: $82.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $195,362.50 |
| Food and Beverage | $16,246.67 |
| Travel and Lodging | $9,447.36 |
| Consulting Fee | $3,420.00 |
| Education | $82.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $230,126.64 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $74,032.08 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $52,822.46 | 2022 | |
| Ucb, INC. | $7,180.37 | 2019-2025 | Briviact, Nayzilam, Zilbrysq |
| Allergan, INC. | $4,901.17 | 2020-2021 | |
| Sk Life Science, INC. | $1,926.03 | 2020-2025 | Xcopri |
| Alexion Pharmaceuticals, INC. | $1,546.85 | 2019-2025 | Ultomiris |
| Lundbeck LLC | $1,088.69 | 2020-2025 | Vyepti, Rexulti |
| Amgen INC. | $1,071.79 | 2019-2025 | Uplizna, Aimovig |
| Acadia Pharmaceuticals INC | $1,048.50 | 2019-2025 | Nuplazid |
| Pfizer INC. | $902.91 | 2019-2025 | |
| Lilly USA, LLC | $886.86 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Eisai INC. | $836.76 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $812.63 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Supernus Pharmaceuticals, INC. | $760.44 | 2019-2022 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $671.36 | 2019-2025 | |
| Nevro Corp. | $608.52 | 2022-2024 | Senza |
| Argenx US, INC. | $599.36 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Mdd US Operations, LLC | $468.04 | 2022-2024 | Gocovri, Apokyn, Xadago |
| Biogen, INC. | $465.23 | 2019-2025 | Vumerity, Tysabri |
| Neurelis, INC. | $449.33 | 2021-2025 | Valtoco |
| Emd Serono, INC. | $352.59 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $258.07 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $207.61 | 2023-2025 | Rexulti, Nuedexta |
| Csl Behring | $164.25 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $157.46 | 2022-2023 | Onzetra Xsail |
| Idorsia Pharmaceuticals US INC | $156.17 | 2023 | Quviviq |
| Janssen Biotech, INC. | $139.41 | 2025 | |
| Livanova USA, INC. | $115.52 | 2019-2022 | |
| Impel Pharmaceuticals INC. | $111.06 | 2022-2023 | Trudhesa |
| Tanabe Pharma America, INC. | $108.91 | 2019-2025 | Radicava |
| Genzyme Corporation | $100.29 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $94.78 | 2024-2025 | |
| Endo Pharmaceuticals INC. | $93.16 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $86.25 | 2022 | |
| Zyla Life Sciences, INC. | $74.31 | 2019-2020 | |
| Ge Healthcare | $72.91 | 2022-2025 | |
| Acorda Therapeutics, INC | $67.13 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.00 | 2022-2025 | Hyqvia, Trintellix |
| Grifols USA, LLC | $60.09 | 2021-2024 | Gamunex-C |
| Sumitomo Pharma America, INC. | $54.50 | 2024 | Aptiom |
| Upsher-Smith Laboratories LLC | $48.93 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $42.83 | 2022-2023 | Firdapse |
| Boston Scientific Corporation | $42.65 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $40.66 | 2019 | |
| Avanir Pharmaceuticals, INC. | $33.40 | 2019 | |
| Mallinckrodt Enterprises LLC | $32.86 | 2019 | |
| Alnylam Pharmaceuticals INC. | $28.48 | 2022 | |
| Abbott Laboratories | $24.50 | 2024 | Infinity |
| Life Molecular Imaging Ltd | $22.44 | 2025 | Neuraceq |
| Azurity Pharmaceuticals, INC. | $21.42 | 2024 | |
| Kedrion Biopharma, INC. | $19.63 | 2025 | Albuked, Rhogam Ultra-Filtered Plus, Kedrab |
| Neuronetics, INC. | $19.47 | 2020 | |
| Sonex Health, INC. | $18.62 | 2025 | Sx-One Microknife |
| Shire North American Group INC | $16.81 | 2019 | |
| Amylyx Pharmaceuticals, INC. | $14.28 | 2023 | Relyvrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hayden Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.